Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) and 2seventy bio (NASDAQ: TSVT) announced positive topline results from the Phase 3 KarMMa-3 study, evaluating Abecma (idecabtagene vicleucel) in relapsed and refractory multiple myeloma. The trial met its primary endpoint, showing statistically significant improvement in progression-free survival versus standard treatments. Key secondary endpoints, including overall response rate, also showed improvement. No new safety signals were reported, confirming Abecma's well-established safety profile.
Bristol Myers Squibb (NYSE: BMY) announced a virtual Investor Event on August 28, 2022, at 7:00 p.m. CET / 1:00 p.m. ET. The event will discuss data from the AXIOMATIC-SSP Phase 2 trial of milvexian for secondary stroke prevention presented at the European Society of Cardiology Congress 2022 in Barcelona, Spain. Executives will offer insights on the data and answer investor questions. Interested parties can access the live webcast on the company's investor relations website, with archived content available later the same day.
Bristol Myers Squibb (NYSE: BMY) announced that Part A of the Phase 3 CheckMate -914 trial did not meet its primary endpoint of disease-free survival for the combination therapy of Opdivo and Yervoy in patients with localized renal cell carcinoma after kidney surgery. Despite previous successes in treating other stages of RCC, this trial's outcome is disappointing. The company remains committed to research in this area and will evaluate the data for further insights.
Bristol Myers Squibb (NYSE:BMY) reported Q2 2022 revenues of $11.9 billion, a 2% year-over-year increase, or 5% when adjusted for foreign exchange. GAAP EPS rose 40% to $0.66, while non-GAAP EPS reached $1.93, mainly impacted by ($0.14) per share from Acquired IPRD charges. 11% revenue growth was noted in in-line products. The company reaffirmed non-GAAP EPS guidance for 2022 while adjusting GAAP EPS guidance. Additionally, they announced plans to acquire Turning Point Therapeutics (NASDAQ:TPTX) for $4.1 billion, expanding their precision oncology portfolio.
Bristol Myers Squibb (NYSE: BMY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the fixed-dose combination of nivolumab and relatlimab for treating advanced melanoma. This treatment targets adults and adolescents with a tumor cell PD-L1 expression 1%. The recommendation is based on the Phase 2/3 RELATIVITY-047 trial results, which demonstrated over twofold increased median progression-free survival compared to nivolumab monotherapy. This would mark the first LAG-3 antibody combination approved in Europe.
Bristol Myers Squibb (BMY) has announced a three-year exclusive collaboration with Jack and Jill of America, Inc. aimed at enhancing diversity within the biopharma sector. This partnership will launch at the "Power of a Dream" National Convention in Orlando, Florida, from July 26-31. The initiative seeks to inspire more Black and African American youth to enter the biopharma industry, emphasizing health equity and better outcomes for marginalized communities. This aligns with BMY's commitment to fostering a sustainable pipeline of diverse talent from Historically Black Colleges and Universities.
Bristol Myers Squibb (NYSE:BMY) has announced an extension of its offer to acquire Turning Point Therapeutics (NASDAQ:TPTX) until August 15, 2022. The offer price remains at $76.00 per share in cash, previously set to expire on July 18, 2022. As of the last update, 34,447,733 shares, approximately 69.0% of Turning Point's outstanding shares, were tendered. The acquisition is anticipated to close in the third quarter of 2022, subject to various regulatory conditions.
Bristol Myers Squibb (NYSE: BMY) has announced the FDA's approval of Breyanzi (lisocabtagene maraleucel), a CAR T cell therapy specifically for adult patients with large B-cell lymphoma (LBCL). This approval is rooted in pivotal trial data demonstrating a median event-free survival of 10.1 months for Breyanzi versus 2.3 months for standard care, highlighting its significant efficacy. Notably, Breyanzi now features the broadest patient eligibility criteria among CAR T therapies for relapsed or refractory LBCL, marking a milestone in cancer treatment innovation.
Bristol Myers Squibb (NYSE:BMY) announced new findings from the Zeposia (ozanimod) Phase 3 DAYBREAK trial, demonstrating cognitive benefits for patients with relapsing multiple sclerosis (MS). In patients with high thalamic volume, 45.5% showed improvement in cognitive function at Month 48. Zeposia was well tolerated, with over 80% of participants remaining on treatment through 48 months. These results highlight the importance of early treatment in preserving cognitive function, which will be presented at the European Academy of Neurology Congress in Vienna, Austria.
Bristol Myers Squibb (NYSE:BMY) released new data on COVID-19 vaccine responses in participants treated with Zeposia (ozanimod) in the ongoing Phase 3 DAYBREAK trial for relapsing multiple sclerosis. The study indicated a 100% seroconversion rate in participants receiving mRNA vaccines, while 62% for non-mRNA vaccine recipients. Results show higher antibody levels in mRNA vaccine recipients, suggesting patients on Zeposia may benefit from booster doses. Findings will be presented on June 28, 2022, at the European Academy of Neurology Congress in Vienna.